AstraZenca rallies on receiving nod from Drug Controller

AstraZeneca Pharma India has received import and market permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India.

The permission now allows the company to import and market FDC of Dapagliflozin 10 mg plus Saxagliptin 5mg film coated tablets. The receipt of this Import and Market permission paves way for the launch of FDC of Dapagliflozin 10 mg plus Saxagliptin 5 mg film coated tablets (QTERN) in India.

FDC of Dapagliflozin 10 mg plus Saxagliptin 5 mg is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM).

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

The shares of AstraZeneca Pharma on Thursday opened at Rs. 2193 against Wednesday’s close of Rs. 2151.70. At 11:26 hours, the stock was trading at Rs. 2233.35, gaining 3.79 per cent from its previous close. The stock hit an intraday high of Rs. 2243.75 and intraday low was Rs. 2185.10. Its 52-week high was Rs. 2,398.55 and 52-week low was Rs. 1,306.80 per share on the BSE.